Skip to main content

Table 3 Effect of albendazole treatment on antibody levels against GMZ2 and constituent in Na/Pf co-infected individuals

From: Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens

Vaccine antigens Pretreatment (n = 57)
(Median [IQR])
Post treatment (n = 57)
(Median [IQR])
P-value
GMZ2
 IgG1 38.2(10.2,90.6) 30.0(11.2,66.8) 0.002
 IgG3 34.6(4.5, 142.0) 28.3(2.7121.3) 0.041
 IgM 192.5(137.3326.2) 212.6(106.9400.0) 0.403
GLURP R0
 IgG1 8.5(2.6,29.0) 8.2(0.9,24.3) 0.647
 IgG3 14.3(2.0,45.4) 13.6(3.00,30.6) 0.024
 IgM 155.8(88.8375.1) 139.5(81.2, 385.8) 0.184
MSP3
 IgG1 56.2(28.5143.8) 41.7(28.0,52.7) < 0.001
 IgG3 44.9(8.3167.2) 50.1(23.9, 128.2) 0.130
 IgM 332.8(269.2452.8) 36.3(10.6149.2) < 0.001
  1. Values are median (quartile). P-values were calculated using the Wilcoxon Signed Ranks Test
  2. This analysis was done for those with hookworm and malaria parasites co-infection; pre-treatment (n = 57) and post-treatment (n = 57). Six individuals were lost during the post-treatment follow up
  3. Abbreviations: LQ Lower Quartile, UQ Upper Quartile